# EDGAR Filing Document

**Accession Number:** 0001957912
**File Stem:** 0001957912-25-000007
**Filing Date:** 2025-10
**Character Count:** 13996
**Document Hash:** 76402c0d8ff1a4fc7920f1d9d4e842fe
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001957912-25-000007.hdr.sgml**: 20251031

**ACCESSION NUMBER**: 0001957912-25-000007

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251031

**DATE AS OF CHANGE**: 20251031

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Neuphoria Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001191070
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93208
- **FILM NUMBER:** 251440936

**BUSINESS ADDRESS:**
- **STREET 1:** 100 SUMMIT DR
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803
- **BUSINESS PHONE:** 781-439-5551

**MAIL ADDRESS:**
- **STREET 1:** 100 SUMMIT DR
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BIONOMICS LIMITED/FI
- **DATE OF NAME CHANGE:** 20020920
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Baselake Partners, LP
- **CENTRAL INDEX KEY:** 0001957912

**ORGANIZATION NAME:**
- **EIN:** 920901824
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G

**BUSINESS ADDRESS:**
- **STREET 1:** 3155 W. BIG BEAVER ROAD, SUITE 207
- **CITY:** TROY
- **STATE:** MI
- **ZIP:** 48084
- **BUSINESS PHONE:** (734) 649-4634

**MAIL ADDRESS:**
- **STREET 1:** 3155 W. BIG BEAVER ROAD, SUITE 207
- **CITY:** TROY
- **STATE:** MI
- **ZIP:** 48084

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Huron Associates, LP
- **DATE OF NAME CHANGE:** 20221212

## Ex-1

Exhibit I

JOINT FILING STATEMENT

PURSUANT TO RULE 13D-1(K)(1)

The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Shares of Neuphoria Therapeutics Inc. together with any or all amendments thereto, when and if required. The parties hereto further consent and agree to file this Joint Filing Statement pursuant to Rule13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule 13G.

This Joint Filing Statement may be terminated by any of the undersigned upon written notice or such lesser period of notice as the undersigned may mutually agree.

Dated: October 31, 2025

---

| | |
|:---|:---|
| Baselake Partners, LP | Baselake Partners, LP |
| By: | */s/ David Paolella* |
|  | David Paolella, Managing Member of Baselake Management, LLC, its investment manager |
| Baselake Management, LLC | Baselake Management, LLC |
| By: | */s/ David Paolella* |
|  | David Paolella, Managing Member |
| David Paolella | David Paolella |
| By: | */s/ David Paolella* |
|  | Individually |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**Issuer:** Neuphoria Therapeutics Inc.

**Title of Class of Securities:** Common Stock, $0.00001 par value per share

**CUSIP Number:** 64136E102

**Date of Event Which Requires Filing of this Statement:** 10/27/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Baselake Partners, LP | Names of Reporting Persons<br>Baselake Partners, LP |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>222222 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>222222 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>222222 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>222222 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.4% | Percent of Class Represented by Amount in Row (9)<br>9.4% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** Please see note in Item 4(a)

---

| 1. | Names of Reporting Persons<br>Baselake Management, LLC | Names of Reporting Persons<br>Baselake Management, LLC |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>222222 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>222222 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>222222 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>222222 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.4% | Percent of Class Represented by Amount in Row (9)<br>9.4% |
| 12. | Type of Reporting Person (See Instructions)<br>IA, OO | Type of Reporting Person (See Instructions)<br>IA, OO |

**Comment for Type of Reporting Person:** Please see note in Item 4(a)

---

| 1. | Names of Reporting Persons<br>David Paolella | Names of Reporting Persons<br>David Paolella |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>222222 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>222222 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>222222 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>222222 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.4% | Percent of Class Represented by Amount in Row (9)<br>9.4% |
| 12. | Type of Reporting Person (See Instructions)<br>HC, IN | Type of Reporting Person (See Instructions)<br>HC, IN |

**Comment for Type of Reporting Person:** Please see note in Item 4(a)

---

**Item 1(a). Name of Issuer:**
Neuphoria Therapeutics Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
100 Summit Drive
Burlington, Massachusetts 01803

**Item 2(a). Name of Person Filing:**
Baselake Partners, LP*
Baselake Management, LLC*
David Paolella*

**Item 2(b). Address of Principal Business Office:**
3155 W. Big Beaver Road, Suite 207, Troy, Michigan 48084

**Item 2(c). Citizenship:**
Baselake Partners, LP - Delaware
Baselake Management, LLC - Delaware
David Paolella - United States of America

**Item 2(d). Title of Class of Securities:**
Common Stock, $0.00001 par value per share

**Item 2(e). CUSIP Number:**
64136E102

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

Baselake Partners, LP - 222,222*
Baselake Management, LLC - 222,222*
David Paolella - 222,222*
The Common Stock (the "Shares") reported as of the filing date are held by Baselake Partners, LP (the "Fund"). Baselake Management, LLC serves as the investment manager to the Fund (the "Investment Manager"). David Paolella serves as the managing member of the Investment Manager (the "Managing Member," and collectively with the Fund and the Investment Manager, the "Reporting Persons").  By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the Shares owned directly by the Fund. The percentages reported herein are calculated based upon a statement in the Issuer's 10-K, indicating that there are 2,357,613 Shares issued and outstanding as of September 29, 2025. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the Shares for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of the Reporting Persons pecuniary interest therein.

**(b) Percent of class:**

Baselake Partners, LP - 9.4%*
Baselake Management, LLC - 9.4%*
David Paolella - 9.4%*

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

Baselake Partners, LP - 0
Baselake Management, LLC - 0
David Paolella - 0

**(ii) Shared power to vote or to direct the vote:**

Baselake Partners, LP - 222,222*
Baselake Management, LLC - 222,222*
David Paolella - 222,222*

**(iii) Sole power to dispose or to direct the disposition of:**

Baselake Partners, LP - 0
Baselake Management, LLC - 0
David Paolella - 0

**(iv) Shared power to dispose or to direct the disposition of:**

Baselake Partners, LP - 222,222*
Baselake Management, LLC - 222,222*
David Paolella - 222,222*

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Baselake Partners, LP**

**Date:** 10/31/2025

**By:** /s/ David Paolella

**Name & Title:** David Paolella, Managing Member of Baselake Management, LLC, its investment manager

**Baselake Management, LLC**

**Date:** 10/31/2025

**By:** /s/ David Paolella

**Name & Title:** David Paolella, Managing Member

**David Paolella**

**Date:** 10/31/2025

**By:** /s/ David Paolella

**Name & Title:** Individually